AbClon Inc
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is… Read more
AbClon Inc (174900) - Total Liabilities
Latest total liabilities as of September 2025: ₩9.44 Billion KRW
Based on the latest financial reports, AbClon Inc (174900) has total liabilities worth ₩9.44 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AbClon Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how AbClon Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AbClon Inc Competitors by Total Liabilities
The table below lists competitors of AbClon Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Orient Semiconductor Electronics Ltd
TW:2329
|
Taiwan | NT$9.16 Billion |
|
Shanghai Shyndec Pharmaceutical Co Ltd
SHG:600420
|
China | CN¥3.63 Billion |
|
Googol Technology Co Ltd Class A
SHE:301510
|
China | CN¥195.92 Million |
|
Jingjin Environmental Protection Co Ltd
SHG:603279
|
China | CN¥4.53 Billion |
|
Taiwan Secom Co Ltd
TW:9917
|
Taiwan | NT$16.47 Billion |
|
Paramount Resources Ltd.
PINK:PRMRF
|
USA | $874.14 Million |
|
MUANGTHAI CAPITAL PCL-NVDR
BK:MTC-R
|
Thailand | ฿135.34 Billion |
|
Bursa Malaysia Bhd Ord
PINK:BSMAF
|
USA | $2.42 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down AbClon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AbClon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AbClon Inc (2015–2024)
The table below shows the annual total liabilities of AbClon Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩18.78 Billion | +3.24% |
| 2023-12-31 | ₩18.19 Billion | +4.18% |
| 2022-12-31 | ₩17.46 Billion | +66.76% |
| 2021-12-31 | ₩10.47 Billion | -3.07% |
| 2020-12-31 | ₩10.80 Billion | -6.81% |
| 2019-12-31 | ₩11.59 Billion | +15.84% |
| 2018-12-31 | ₩10.00 Billion | +188.10% |
| 2017-12-31 | ₩3.47 Billion | -13.84% |
| 2016-12-31 | ₩4.03 Billion | +40.95% |
| 2015-12-31 | ₩2.86 Billion | -- |